CD276 and prostate cancer: Roth et al(17) evaluated B7-H3 immunoreactivity in >300 patients who suffered from prostate cancer and underwent radical prostatectomy, and indicated that increased levels of B7-H3 intensity correlated with worsened clinicopathological features as well as a poorer postoperative prognosis.